X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB VENUS REMEDIES UNICHEM LAB/
VENUS REMEDIES
 
P/E (TTM) x -33.5 -3.4 - View Chart
P/BV x 0.7 0.1 569.9% View Chart
Dividend Yield % 2.3 0.0 -  

Financials

 UNICHEM LAB   VENUS REMEDIES
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
VENUS REMEDIES
Mar-18
UNICHEM LAB/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs382126 303.4%   
Low Rs23461 383.1%   
Sales per share (Unadj.) Rs116.3301.8 38.5%  
Earnings per share (Unadj.) Rs-18.9-24.9 76.1%  
Cash flow per share (Unadj.) Rs-11.72.5 -461.4%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.60-  
Book value per share (Unadj.) Rs381.0293.3 129.9%  
Shares outstanding (eoy) m70.3412.34 570.0%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.60.3 855.0%   
Avg P/E ratio x-16.3-3.8 433.1%  
P/CF ratio (eoy) x-26.236.7 -71.4%  
Price / Book Value ratio x0.80.3 253.6%  
Dividend payout %-26.40-   
Avg Mkt Cap Rs m21,6681,154 1,878.0%   
No. of employees `0002.30.9 246.5%   
Total wages/salary Rs m2,006393 510.4%   
Avg. sales/employee Rs Th3,587.84,026.1 89.1%   
Avg. wages/employee Rs Th880.0425.0 207.1%   
Avg. net profit/employee Rs Th-583.7-331.8 175.9%   
INCOME DATA
Net Sales Rs m8,1803,724 219.7%  
Other income Rs m61023 2,711.6%   
Total revenues Rs m8,7903,747 234.6%   
Gross profit Rs m-1,320395 -334.4%  
Depreciation Rs m505338 149.3%   
Interest Rs m80354 22.6%   
Profit before tax Rs m-1,295-275 470.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3332 105.8%   
Profit after tax Rs m-1,331-307 433.7%  
Gross profit margin %-16.110.6 -152.2%  
Effective tax rate %-2.6-11.5 22.5%   
Net profit margin %-16.3-8.2 197.4%  
BALANCE SHEET DATA
Current assets Rs m23,3182,638 884.0%   
Current liabilities Rs m4,6352,305 201.1%   
Net working cap to sales %228.48.9 2,554.0%  
Current ratio x5.01.1 439.5%  
Inventory Days Days122135 89.9%  
Debtors Days Days12146 262.2%  
Net fixed assets Rs m8,1634,871 167.6%   
Share capital Rs m141123 114.0%   
"Free" reserves Rs m26,6603,496 762.7%   
Net worth Rs m26,8013,619 740.5%   
Long term debt Rs m31,374 0.2%   
Total assets Rs m31,8907,509 424.7%  
Interest coverage x-15.20.2 -6,803.9%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.30.5 51.7%   
Return on assets %-3.90.6 -621.3%  
Return on equity %-5.0-8.5 58.6%  
Return on capital %-4.51.6 -287.1%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m4,3560-   
Fx outflow Rs m0517 0.0%   
Net fx Rs m4,356-517 -843.4%   
CASH FLOW
From Operations Rs m-1,123514 -218.4%  
From Investments Rs m16,487-123 -13,392.9%  
From Financial Activity Rs m-8,811-387 2,276.2%  
Net Cashflow Rs m6,5524 156,000.0%  

Share Holding

Indian Promoters % 50.1 32.9 152.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 0.2 8,388.9%  
FIIs % 3.0 0.6 517.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 66.4 47.7%  
Shareholders   20,176 20,121 100.3%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   PIRAMAL ENTERPRISES  GSK PHARMA  PANACEA BIOTECH  DR. REDDYS LAB  ABBOTT INDIA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Finish Flat; IT and Pharma Stocks Witness Selling(Closing)

Share markets in India ended their trading session on a flattish note. Sectoral indices ended on a mixed note with stocks in the IT sector and pharma sector witnessing most of the selling pressure.

Related Views on News

UNICHEM LAB Announces Quarterly Results (2QFY19); Net Profit Down 61.4% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, UNICHEM LAB has posted a net profit of Rs 177 m (down 61.4% YoY). Sales on the other hand came in at Rs 2 bn (down 42.6% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Nov 14, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 5-YR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS